Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Cancer clinical trials are said to be the “gold standard” for developing new therapies for cancer patients. Unfortunately, study after study documents deficiencies, bias, and other failings of clinical trails for cancer therapies.
The study linked and excerpted below describes how cancer clinical trials are fraught with documented heart damage that does not get reported.
I was diagnosed with an incurable blood cancer called multiple myeloma in early 1994. I underwent the FDA approved standard-of-care therapy plan of induction therapy. I followed induction therapy with an autologous stem cell transplant. The ASCT included both melphalan and busulphan. Both regimens are cardiotoxic.
My ASCT was preceded by two rounds of high-dose cytoxan. Another cardiotoxic chemo regimen. I was diagnosed with chemotherapy-induced cardiomyopathy in early 2011 fully 15 years after my induction therapy and ASCT.
“Providers, both cancer and noncancer, generally put cardiotoxicity in the box of anthracyclines and radiation, but particularly over the last decade, we’ve begun to understand it’s well beyond any one class of drugs,” Addison said.”
Did my oncologists not know about the damage they were potentially causing my heart? Did they think I wasn’t going to live very long anyhow?
How much responsibility should oncologists have if they run a clinical trial or prescribe therapy that causes heart damage to patients?
If you are about to enroll in a cancer clinical trial or if you are a MM patient about to undergo any of the cardiotoxic regimens listed above, consider embarking on a heart healthy lifestyle, especially while you are undergoing any cardiotoxic regimens.
Consider:
If you would like to learn more about evidence-based non-conventional therapies to enhance heart health email me at David.PeopleBeatingCancer@gmail.com
Thank you,
David Emerson
“Clinical trials supporting FDA approval of contemporary cancer therapies frequently failed to capture major adverse cardiovascular events (MACE) and, when they did, reported rates 2.6-fold lower than noncancer trials, new research shows.
Overall, 51.3% of trials did not report MACE, with that number reaching 57.6% in trials enrolling patients with baseline CVD.
Nearly 40% of trials did not report any CVD events in follow-up, the authors report online February 10 in the Journal of the American College of Cardiology.
“Even in drug classes where there were established or emerging associations with cardiotoxic events, often there were no reported heart events or cardiovascular events across years of follow-up in trials that examined hundreds or even thousands of patients…
‘How do we really know for sure that the trial actually reflects the true risk of heart events?’ to which I told him, ‘It’s difficult to know’,” he said.
“I think many of us rely heavily on what we see in the trials, particularly when they make it to the top journals, and quite frankly, we generally take it at face value,” Addison observed…
Over 148,138 person-years of follow-up (median trial duration, 30 months), there were 1148 incidents of MACE
MACE rates were higher in the intervention group than in the control group (792 vs 356; P < .01).
Among the 64 trials that excluded patients with baseline CVD, there were 269 incidents of MACE…
“Closer collaboration between cardiologists and cancer physicians is needed to better determine true cardiac risks among patients treated with these drugs.”
Part of the problem may be that some of the toxicities, particularly cardiovascular, may not emerge for years, he said. Participant screening for the trials also likely removed patients with high cardiovascular risk…
The underreported CVD events may also reflect the rapidly changing profile of cardiovascular toxicities associated with novel anticancer therapies.
“Providers, both cancer and noncancer, generally put cardiotoxicity in the box of anthracyclines and radiation, but particularly over the last decade, we’ve begun to understand it’s well beyond any one class of drugs,” Addison said…
“Initial drugs like anthracyclines or Herceptin in cardio-oncology were associated with systolic cardiac dysfunction, whereas the majority of issues we see in the cardio-oncology clinics today are vascular, metabolic, arrhythmogenic, and inflammatory,” he told theheart.org | Medscape Cardiology. “Echocardiography misses the big and increasingly complex picture.”
His group, for example, has been studying myocarditis associated with immunotherapies, but none of the clinical trials require screening or surveillance for myocarditis with a cardiac biomarker like troponin.
The group also recently identified 303 deaths in patients exposed to ibrutinib, a drug that revolutionized the treatment of several B-cell malignancies but is associated with higher rates of atrial fibrillation, which is also associated with increased bleeding risk. “So there’s a little bit of a double whammy there, given that we often treat atrial fibrillation with anticoagulation and where we can cause complications in patients,” Moslehi noted…